Droplet Digital PCR Patents: Who Leads, Where the Gaps Are 2026
- Filing peaked in 2019 at 336 records, then eased to 199 by 2024 — a 33% pullback over that three-year span, not a collapse of interest.
- The leader holds 225 families, but the top 5 combined account for only 22.1% of all 2,628 records — this field has a long tail, not a single gatekeeper.
- C12Q enzyme/DNA assay claims cover 61.8% of records, while bioinformatics (G16B) sits at just 5.4% — the analysis layer is comparatively open.
Filing growth compares 2021 (295 records) with 2024 (199) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 2,628 records in scope (CR5), not by the ranked leaders only.
What the droplet digital PCR patent record shows
Droplet digital PCR (ddPCR) partitions a reaction into thousands of nanoliter droplets, amplifies each independently, and counts positive versus negative droplets to give an absolute molecule count without a standard curve. The patent record in scope spans 2,628 families published between 2015 and mid-2026, covering droplet generation and stability, partition volume control, reaction chemistry, imaging and readout hardware, and downstream diagnostic and research applications. Publication lags filing by roughly 18 months, so the most recent one to two years in any trend undercounts true filing activity.
Claim density is heaviest where enzymatic assay chemistry meets genetic engineering — the two largest IPC subclasses in this dataset — while hardware, bioinformatics and lab apparatus classes are filed far less often. That split matters for anyone scoping freedom to operate: the wet-chemistry core is congested, but the instrumentation and software layers around it carry comparatively less claim coverage per record.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
Two views of the same 2,628-record dataset: how filing volume has moved year over year, and how records distribute across IPC subclasses.
Filing trend, 2017-2026
Filings ran from 184 in 2017 to a peak of 336 in 2019, then declined to 199 by 2024 — a 33% drop across that three-year window. 2025 and 2026 figures are still incomplete because of publication lag and should not be read as a further decline.
IPC subclass composition
C12Q (enzyme/DNA measurement) appears in 61.8% of records and C12N (genetic engineering) in 33.2%, making the core assay chemistry the densest claim territory. Hardware-adjacent classes such as B01L (lab apparatus, 7.5%) and G16B (bioinformatics, 5.4%) are filed far less often, since a record can carry multiple classes these shares sum above 100%.
Shares are the percentage of the 2,628 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Droplet Digital PCR with Eureka
This page is one run against one query. Ask Eureka your own question about droplet digital pcr and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records in the ddPCR corpus
Rapid detection method of Weissella viridescens based on droplet digital PCR (ZA202109144B)
The filing discloses a method for detecting Weissella viridescens using conserved-sequence primers and probes, amplifying extracted genomic DNA by droplet digital PCR, then reading each droplet individually with a droplet analyzer to classify fluorescence-positive droplets as target-present.Assignee and filing date are shown in the table above.
View full filing| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20120316074A1 | Methods and compositions for nucleic acid analysis | 569 |
| 2 | WO2012149042A2 | Methods and compositions for nucleic acid analysis | 412 |
| 3 | WO2020123320A2 | Imaging system hardware | 289 |
| 4 | US20110159499A1 | Methods and compositions for detecting genetic material | 267 |
| 5 | WO2011066476A1 | Methods and compositions for detecting genetic material | 245 |
| 6 | US20210189475A1 | Imaging system hardware | 212 |
| 7 | US9347059B2 | Methods and compositions for nucleic acid analysis | 211 |
| 8 | WO2018041973A1 | Chemically modified single-stranded RNA-editing oligonucleotides | 191 |
| 9 | WO2012112970A2 | Methods and compositions for detecting genetic material | 189 |
| 10 | US20160231324A1 | Encapsulated sensors and sensing systems for bioassays and diagnostics and methods for making and using them | 188 |
Citation counts reflect influence within the searched corpus and skew toward older filings; treat them as a signal of prior significance, not current commercial weight.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for filing strategy
Three patterns stand out once the raw counts are put next to each other: where volume concentrates, where it is thinning, and where the underlying chemistry versus hardware split creates room to file.
Leadership is real but not exclusive
The leading assignee holds 225 families and the top 5 combined reach 581 records, 22.1% of the full dataset. That leaves nearly four-fifths of filings spread across a long tail of single- and few-filing entrants, which is unusual for a technique this well established.
Volume is normalising, not disappearing
Filings peaked at 336 in 2019 and had fallen to 199 by 2024, a 33% decline over that three-year span. That reading stops at 2024 deliberately: 2025-2026 counts are still filling in under normal publication lag and should not be read as continued decline.
Chemistry is congested, analytics is not
C12Q assay-chemistry claims touch 61.8% of the 2,628 records while G16B bioinformatics touches only 5.4%. Readout algorithms, calling thresholds for ambiguous ('rain') droplets, and downstream data pipelines carry comparatively light claim coverage relative to the wet-lab core.
US and Europe dominate filing venues
The United States receives the largest single share of filings at 686 records, followed by the EPO at 524 and WIPO/PCT at 483, with Canada, Australia and Israel each in the low hundreds. Venue choice tracks closely with where diagnostic and clinical validation markets sit.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to droplet digital pcr, with the prior art for and against each one.
Who is filing, and where the field is still open
Assignee concentration and co-filing patterns point to a field with a handful of established programmes surrounded by many smaller, often single-filing entrants — a structure that leaves specific sub-areas genuinely under-claimed.
A single leader, well ahead of the field
The top-ranked assignee holds 225 families, more than four times the fifth-place holder's 52. That gap suggests one organisation built an early, broad filing programme around core droplet generation and assay chemistry rather than a narrow set of claims.
Most of the field sits outside the top 10
The ranking returned by the dataset covers 100 companies, and the top 10 combined account for only 30.1% of all 2,628 records. The remaining 90 ranked assignees, plus unranked filers, hold the bulk of activity — a structure closer to a fragmented research field than a consolidated industry.
Co-filing is concentrated among a few academic-industry links
Only 10 co-assignee pairs appear in the dataset, and the strongest of them recurs across dozens of shared filings. That pattern points to a small number of durable academic-industry partnerships rather than broad cross-licensing norms across the field.
| Assignee | Recent year | YoY |
|---|---|---|
| The Regents of the University of California | 1 | -50% |
| Juno Therapeutics, Inc. | 1 | -50% |
| The General Hospital Corporation | 1 | 0% |
| Bio-Rad Laboratories, Inc. | 0 | -100% |
| PROQR THERAPEUTICS II BV | 0 | -100% |
| DropWorks, Inc. | 0 | — |
| Mestone Bio, Inc. | 0 | -100% |
| California Institute of Technology | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, licensing, or identifying a first-filing opportunity.
Map claims against the C12Q core
Given that 61.8% of records touch C12Q, a freedom-to-operate review should start there before checking adjacent classes, since assay-chemistry claims are most likely to overlap with any new filing.
Explore claim charts in EurekaTrack the leading assignee's recent momentum
The leading assignee's filing rate has itself slowed in the latest year; watching whether that continues or reverses will signal whether the field is consolidating further or opening up.
Set up assignee monitoring in EurekaScope a first filing in bioinformatics or hardware
G16B and B01L classes carry the lightest claim density of the eight subclasses tracked here, making them the more realistic place to draft a defensible first claim.
Draft a claim scope in EurekaCommon questions about ddPCR patents
One assignee leads the ranked field with 225 families, well ahead of the fifth-place holder at 52. However, the top 5 assignees combined account for only 22.1% of the 2,628 records in scope, so no single company controls the field outright. The remaining filings are spread across a long tail of 90-plus other ranked assignees and unranked entrants, which means competitive monitoring needs to look beyond the top few names.
Filing peaked in 2019 at 336 records and had fallen to 199 by 2024, a 33% decline over that three-year span. That decline should be read carefully: publication typically lags filing by about 18 months, so 2025 and 2026 figures in any dataset are still incomplete and cannot yet be read as continued decline. The honest read is that filing has normalised from an early peak, not that interest has disappeared.
Bioinformatics classified under G16B appears in only 5.4% of the 2,628 records, and lab apparatus under B01L in 7.5%, compared with 61.8% for core assay chemistry under C12Q. That gap suggests readout algorithms, rain-artifact classification, and low-cost partitioning hardware carry lighter claim density than the underlying chemistry, making them more realistic areas for a new first filing.
The United States receives the largest share of filings among receiving offices tracked, at 686 records, followed by the EPO at 524 and the WIPO/PCT route at 483. Canada, Australia and Israel each sit in the low hundreds. This distribution generally tracks where diagnostic approval pathways and clinical adoption are concentrated.
The most-cited records in this corpus, including US20120316074A1 and its related family members, cover foundational methods and compositions for nucleic acid analysis using droplet partitioning, cited 569 and 412 times respectively within the searched corpus. High citation counts reflect influence within older, foundational filings rather than current market weight, since citation metrics inherently favour records that have had more time to accumulate references. Anyone designing new droplet-based assay chemistry should check these families specifically for overlap with core partitioning and detection claims before assuming a new sub-application is clear.
Research Droplet Digital PCR in depth with Eureka
Go past this page: query the whole droplet digital pcr corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.